ReviewCurrent diabetes reviews2015
Addressing unmet medical needs in type 2 diabetes: a narrative review of drugs under development.
Review in Current diabetes reviews, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 49 citations in OpenAlex.
- Dietary Supplements Derived from Food By-Products for the Management of Diabetes Mellitus.Antioxidants (Basel, Switzerland) · 2025Review
- The genetic architecture of biological age in nine human organ systems.Nature aging · 2024Article
- The Genetic Architecture of Biological Age in Nine Human Organ Systems.medRxiv : the preprint server for health sciences · 2024Article
- Small molecule SWELL1 complex induction improves glycemic control and nonalcoholic fatty liver disease in murine Type 2 diabetes.Nature communications · 2022Article
- Quantitative Analysis and Visualization of the Interaction Between Intestinal Microbiota and Type 1 Diabetes in Children Based on Multi-Databases.Frontiers in pediatrics · 2021Article
- Antidiabetic activity in vitro and in vivo of BDB, a selective inhibitor of protein tyrosine phosphatase 1B, from Rhodomela confervoides.British journal of pharmacology · 2020Article
- Altered Metabolome of Lipids and Amino Acids Species: A Source of Early Signature Biomarkers of T2DM.Journal of clinical medicine · 2020Review
- DES1: A Key Driver of Lipotoxicity in Metabolic Disease.DNA and cell biology · 2020Article
- Tyrosine Phosphorylation Regulates Plasma Membrane Expression and Stability of the Human Bile Acid Transporter ASBT (Molecular pharmaceutics · 2019Article
- The role of C16:0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approach.Molecular metabolism · 2019Article
- CYC27 Synthetic Derivative of Bromophenol from Red AlgaMarine drugs · 2019Article
- The New Paradigms in Clinical Research: From Early Access Programs to the Novel Therapeutic Approaches for Unmet Medical Needs.Frontiers in pharmacology · 2019Review
- The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development.International journal of molecular sciences · 2018Review
- Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics.European journal of drug metabolism and pharmacokinetics · 2018Review
- A Narrative Review of Potential Future Antidiabetic Drugs: Should We Expect More?Indian journal of clinical biochemistry : IJCB · 2018Review
- Glucagon-like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naïve Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2017Article
- Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs Under Development.Current diabetes reviews · 2017Review
- Article
- The Potential Therapeutic Application of Peptides and Peptidomimetics in Cardiovascular Disease.Frontiers in pharmacology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global burden of type 2 diabetes is increasing worldwide, and successful treatment of this disease needs constant provision of new drugs. Twelve classes of antidiabetic drugs are currently available, and many new drugs are under clinical development. These include compounds with known mechanisms of action but unique properties, such as once-weekly DPP4 inhibitors or oral insulin. They also include drugs with new mechanisms of action, the focus of this review. Most of these compounds are in Phase 1 and 2, with only a small number having made it to Phase 3 at this time. The new drug classes described include PPAR agonists/modulators, glucokinase activators, glucagon receptor antagonists, anti-inflammatory compounds, G-protein coupled receptor agonists, gastrointestinal peptide agonists other than GLP-1, apical sodium-dependent bile acid transporter (ASBT) inhibitors, SGLT1 and dual SGLT1/SGLT2 inhibitors, and 11beta- HSD1 inhibitors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.